Candel Therapeutics Inc (CADL)
7.97
+0.92
(+13.05%)
USD |
NASDAQ |
May 01, 16:00
7.78
-0.19
(-2.38%)
After-Hours: 18:49
Candel Therapeutics Shareholders Equity (Quarterly): 12.74M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 12.74M |
| September 30, 2023 | 23.02M |
| June 30, 2023 | 30.77M |
| March 31, 2023 | 39.65M |
| December 31, 2022 | 47.71M |
| September 30, 2022 | 52.13M |
| June 30, 2022 | 60.07M |
| Date | Value |
|---|---|
| March 31, 2022 | 63.76M |
| December 31, 2021 | 64.14M |
| September 30, 2021 | 62.99M |
| June 30, 2021 | -43.18M |
| March 31, 2021 | -27.50M |
| December 31, 2020 | -23.56M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-43.18M
Minimum
Jun 2021
64.14M
Maximum
Dec 2021
27.90M
Average
39.65M
Median
Mar 2023
Shareholders Equity (Quarterly) Benchmarks
| Allurion Technologies Inc | -70.49M |
| AngioDynamics Inc | 218.70M |
| Eliem Therapeutics Inc | 107.60M |
| Macrogenics Inc | 152.61M |
| GlycoMimetics Inc | 38.41M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 41.20M |
| Total Liabilities (Quarterly) | 28.46M |